News Releases

SEATTLE --(BUSINESS WIRE)--Jun. 24, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today that the first patient has been dosed in Synergy, a

SEATTLE --(BUSINESS WIRE)--Jun. 8, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today Alpine is set to join the broad-market Russell 3000®

Alpine to hold an ALPN-202 Investor Event on Friday, June 4 at 7:00pm EDT SEATTLE --(BUSINESS WIRE)--Jun. 4, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases,

SEATTLE --(BUSINESS WIRE)--Jun. 2, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today made an oral presentation of preclinical data from the company’s

SEATTLE --(BUSINESS WIRE)--Jun. 2, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the appointment of industry veteran Zelanna Goldberg,

- Alpine to hold Investor Event on Friday, June 4 at 7:00pm ET - - Program abstracts are now live on the ASCO website - SEATTLE --(BUSINESS WIRE)--May 19, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments

SEATTLE --(BUSINESS WIRE)--May 18, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an oral presentation of preclinical data from the

SEATTLE --(BUSINESS WIRE)--May 13, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the

SEATTLE --(BUSINESS WIRE)--Apr. 28, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced an upcoming presentation on NEON-1, the company’s Phase

– NEON-1, clinical trial with ALPN-202 monotherapy, proceeds through dose escalation – – New discovery efforts yield novel preclinical fusion proteins that enable tumor antigen-dependent CD28 costimulation – SEATTLE --(BUSINESS WIRE)--Apr. 12, 2021-- Alpine Immune Sciences, Inc.